Search

Your search keyword '"Focan C"' showing total 441 results

Search Constraints

Start Over You searched for: Author "Focan C" Remove constraint Author: "Focan C"
441 results on '"Focan C"'

Search Results

2. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

4. Patient management after primary rectal cancer diagnosis. Special focus on surgical treatment for non-metastatic disease

5. End-of-life healthcare utilization in older patients with cancer: a large Belgian data linkage study

6. Palliative care at the end-of-life in older patients with cancer and associated age-related factors

7. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV

8. Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up

9. A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators

10. 1265MO Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data

12. General practitioner contacts, hospitalizations, and nursing home transfers in older patients up to three years after new cancer diagnosis: Results from a large data linkage cohort study.

14. Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients

19. SIOG2022-0116 - Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up

28. High-Dose Medroxyprogesterone Acetate as Adjuvant Hormonotherapy in Early Breast Cancer: 9 Years Results of a Multicenter Randomized Trial

29. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions

32. SIOG2021-0161 - Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients

33. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.

34. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

36. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

37. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

38. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

39. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium

40. Quality of life (QoL) in older patients (pts) with cancer and prognostic factors for QoL decline.

41. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

42. Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC)

44. Adherence to geriatric assessment (GA)-based recommendations in older patients (pts) with cancer.

45. Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV).

46. Pharmacogenomic determinants of cetuximab and oxaliplatin pharmacokinetics during combined intravenous cetuximab (IV-Cet) and triplet hepatic artery chronomodulated infusion in patients (pts) with initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU OPTILIV trial).

Catalog

Books, media, physical & digital resources